CR20210432A - Métodos para purificar un extracto de alérgeno - Google Patents

Métodos para purificar un extracto de alérgeno

Info

Publication number
CR20210432A
CR20210432A CR20210432A CR20210432A CR20210432A CR 20210432 A CR20210432 A CR 20210432A CR 20210432 A CR20210432 A CR 20210432A CR 20210432 A CR20210432 A CR 20210432A CR 20210432 A CR20210432 A CR 20210432A
Authority
CR
Costa Rica
Prior art keywords
allergen extract
purifying
methods
allergen
purified
Prior art date
Application number
CR20210432A
Other languages
English (en)
Inventor
SÁNCHEZ Jerónimo CARNÉS
María Teresa Gallego
Marta Román-Escutia
María Morales
Original Assignee
Leti Pharma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Pharma S L filed Critical Leti Pharma S L
Publication of CR20210432A publication Critical patent/CR20210432A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a procesos para producir extractos de alérgenos semipurificados y purificados y composiciones farmacéuticas y vacunas para uso en el diagnóstico y tratamiento de alergia.             En un aspecto de la invención, se proporciona un proceso para producir un extracto de alérgeno despigmentado, el proceso que comprende:             a) basificar un extracto de alérgeno nativo; y             b) remover moléculas que tienen un tamaño molecular de menos de 3,5 kDa; y             c) ajustar el pH a neutralidad;             para producir de este modo un extracto de alérgeno despigmentado.
CR20210432A 2019-01-17 2019-03-26 Métodos para purificar un extracto de alérgeno CR20210432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382030 2019-01-17
PCT/EP2019/057647 WO2020147985A1 (en) 2019-01-17 2019-03-26 Methods of purifying an allergen extract

Publications (1)

Publication Number Publication Date
CR20210432A true CR20210432A (es) 2022-01-05

Family

ID=65279503

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210432A CR20210432A (es) 2019-01-17 2019-03-26 Métodos para purificar un extracto de alérgeno

Country Status (16)

Country Link
US (1) US20220110983A1 (es)
EP (1) EP3911343A1 (es)
JP (1) JP2022523647A (es)
CN (1) CN113825518A (es)
AU (1) AU2019422413A1 (es)
BR (1) BR112021014064A2 (es)
CA (1) CA3126499A1 (es)
CL (1) CL2021001889A1 (es)
CO (1) CO2021010606A2 (es)
CR (1) CR20210432A (es)
EC (1) ECSP21060381A (es)
IL (1) IL284901A (es)
JO (1) JOP20210197A1 (es)
MX (1) MX2021008665A (es)
PE (1) PE20212105A1 (es)
WO (1) WO2020147985A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083497A3 (en) * 1982-01-06 1985-11-06 Beecham Group Plc Process for preparing modified allergens, their use in treating allergic conditions
JP3575802B2 (ja) * 1991-07-12 2004-10-13 イミユロジク・フアーマシユーチカル・コーポレーシヨン 日本杉花粉からのアレルゲン性蛋白質及びペプチド
JP3124344B2 (ja) * 1991-11-06 2001-01-15 フマキラー株式会社 重合ダニアレルゲン
JP3397791B2 (ja) * 1992-09-21 2003-04-21 ラボラトリオス レティ ソシエダッド アノニマ アレルゲンとして活性なタンパク質を含有する水性エキスの精製方法，この方法で得られるエキスならびにそれらの使用
AU675629B2 (en) 1992-09-21 1997-02-13 Laboratorios Leti S.A. A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use
CA2495825C (en) * 2002-08-19 2015-03-17 Merck Patent Gesellschaft Mit Beschraenkter Haftung Variants of the major allergen phl p 1 from timothy grass
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
CA3060638A1 (en) * 2010-02-12 2011-08-18 Laboratorios Leti, S.L. Process for producing an allergen extract
FI20115374A0 (fi) * 2011-04-18 2011-04-18 Teknologian Tutkimuskeskus Vtt Oy Uudet hypoallergeenit
CN102552900A (zh) * 2011-12-21 2012-07-11 北京新华联协和药业有限责任公司 蒿属花粉变应原疫苗及其制备方法和应用
CN103966292A (zh) * 2013-01-31 2014-08-06 中国食品发酵工业研究院 一种过敏原部分消除的适度水解酪蛋白肽工业化制造方法及其应用
ES2503516B1 (es) * 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención

Also Published As

Publication number Publication date
AU2019422413A1 (en) 2021-08-26
CA3126499A1 (en) 2020-07-23
ECSP21060381A (es) 2021-11-18
JP2022523647A (ja) 2022-04-26
EP3911343A1 (en) 2021-11-24
CN113825518A (zh) 2021-12-21
MX2021008665A (es) 2021-10-26
IL284901A (en) 2021-08-31
WO2020147985A1 (en) 2020-07-23
BR112021014064A2 (pt) 2021-09-21
CL2021001889A1 (es) 2022-01-21
CO2021010606A2 (es) 2021-10-29
PE20212105A1 (es) 2021-11-04
US20220110983A1 (en) 2022-04-14
JOP20210197A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
EA201990071A1 (ru) Композиция пептидной вакцины
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
MX2012004625A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
SE1550189A1 (en) Therapeutic and prophylactic composition produced by microbiota
MX2023012271A (es) Medicina terapeutica para enfermedades fibrosas.
WO2017200659A3 (en) A method to enhance wound healing using silk-derived protein
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA201892322A1 (ru) Способ лечения или предупреждения остеоартрита
MX2023008923A (es) Composicion farmaceutica que comprende un derivado de difenilpirazina.
WO2020186155A3 (en) Synthetic neuromodulatory peptides
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
EA201892320A1 (ru) Способ лечения или предупреждения остеоартрита
MX2016007122A (es) Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos.
CR20210432A (es) Métodos para purificar un extracto de alérgeno
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
IL202206A0 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
BR112013023167A2 (pt) método para produção do fator viii humano recombinante, fator viii humano recombinante, produto farmacêutico, uso do fator viii humano recombinante, método para tratamento de doenças relacionadas à diminuição, inativação ou ausência de fator viii, uso da endoprotease spc6 e/ou da pace4 ai e/ou da pacesol e processamento proteolítico do fator viii humano recombinante
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
EP3632450A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE CAUSING FOOT PAIN CONSISTING OF BOTULIC TOXIN AND HYALURONIC ACID AND METHOD OF TREATMENT OF FOOT PAIN USING THE SAME